Pharmacokinetics of Levetiracetam in Neonates with Seizures

Merhar, Stephanie L.; Schibler, Kurt; Sherwin, Catherine M.T.; Meinzen‐Derr, Jareen; Shi, Jing; Balmakund, Tonya; Vinks, Alexander A.

doi:10.1016/j.jpeds.2011.03.057

Cited by 72 publications

(55 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CL/F of this study was lower than in the children in the studies by Toublanc and Chhun [17,18] . In Merhar's study of neonates [24] , clearance was 1.21 mL·min -1 ·kg -1 . In Pellock's study [12] of 6-12 years old, CL/F was 1.43 mL·min -1 ·kg -1 , which was higher than that in adults (0.96 mL·min…”

Section: Patient Datamentioning

confidence: 94%

Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy

Wang

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To establish a population pharmacokinetics (PPK) model of levetiracetam in Chinese children with epilepsy. Methods: A total of 418 samples from 361 epileptic children in Peking University First Hospital were analyzed. These patients were divided into two groups: the PPK model group (n=311) and the PPK validation group (n=50). Levetiracetam concentrations were determined by HPLC. The PPK model of levetiracetam was established using NONMEM, according to a one-compartment model with firstorder absorption and elimination. To validate the model, the mean prediction error (MPE), mean squared prediction error (MSPE), root mean-squared prediction error (RMSPE), weight residues (WRES), and the 95% confidence intervals (95% CI) were calculated. Conclusion:A one-compartment model with first-order absorption adequately described the levetiracetam concentrations. Body weight was identified as a significant covariate for levetiracetam clearance in this study. This model will be valuable to facilitate individualized dosage regimens.

show abstract

Section: Patient Datamentioning

confidence: 94%

Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy

Wang

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…11 Though, there are case series, small trials, including some recent ones on use of levetiracetam in neonatal seizures in term and preterm infants, there are no randomized controlled trials. [12][13][14][15][16][17][18][19] We therefore designed a trial with the objective to compare the efficacy of levetiracetam and phenobarbitone in the treatment of clinically apparent neonatal seizures in term and late preterm neonates.…”

Section: Introductionmentioning

confidence: 99%

A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study

et al. 2016

View full text Add to dashboard Cite

“…Etyolojide hipoglisemi, hipokalsemi, hipomagnezemi pridoksin eksikliği olmadığı dışlanmış ve sonrasında LEV başlanmış, %80'inde birinci haftanın sonunda nöbetler kontrol altına alınmış ve belirgin bir yan etki gözlenmemiş ve yarılanma ömrünün 16-18 saat arası büyük çocuklara göre hafif uzun olduğu bulunmuştur. [9][10][11] Biz de 27 gestayonel haftalık ikiz eşlerinin standart AEİ'lara dirençli nöbetlerinin olması üzerine LEV tedavisi uyguladık.…”

Section: Discussionunclassified

Levetirasetam for the Treatment of Refractor Neonatal Seizures

Keleş¹,

Gebeşçe²,

Yazgan³

2012

Epilepsi

View full text Add to dashboard Cite

ÖzetKonvülsiyonlar yenidoğan döneminde, özellikle prematürelerde sık görülür. Konvansiyonel antiepileptiklerin güvenirliliği ve etkinliği ayrın-tılı olarak araştırılmıştır. Buna rağmen, en sık kullanılan fenobarbitalin bile daha önce bilinmeyen apopitoz gibi uzun dönem yan etkileri yeni fark edilmektedir. Oysa yeni antiepileptiklerden levetirasetamın çocuk ve erişkinlerin parsiyel başlangıçlı, idiyopatik ya da jeneralize nöbet-lerindeki etkinliği ve güvenirliği ile ilgili birçok çalışma yapılmıştır. Ancak yenidoğanlarda özellikle prematürelerdeki çalışmalar sınırlıdır. Bu yazıda klasik antiepileptiklerere cevap vermeyen, ancak levetirasetamla nöbetleri kontrol altına alınan yedi günlük ikiz prematüre olgular sunuldu. Her iki hastanın uzun süreli takiplerinde nöbet ve ilaca bağlı her hangi bir yan etki gözlenmedi.Anahtar sözcükler: Dirençli nöbet; levetirasetam; yenidoğan. SummaryConvulsions are observed commonly in newborns and especially in premature babies. The afety and efficiency of conventional antiepileptic drugs have been extensively investigated. But long term side effects like apoptosis are newly recognized even with the the most commonly used antiepilectic drug, phenobarbital. Much research is related to the safety and efficiency of levetiracetam, one of the recent antiepileptic drugs, used in partial onset idiopathic or generalized seizures of adults and children. However, research on newborns, especially premature newborns is limited. In this paper we present two cases involving seven day newborn premature twins treated with refractory seizures. Seizures were controlled only with levetiracetam therapy. We did not observe any long term side effects which can be related to levetiracetam or seizures in a long term follow up of both patients.

show abstract

Pharmacokinetics of Levetiracetam in Neonates with Seizures

Abstract: The pharmacokinetics of levetiracetam were determined prospectively in 18 neonates with seizures. Neonates were found to have lower clearance, higher volume of distribution, and a longer half-life as compared with older children and adults. Mild somnolence was the only adverse effect.

Cited by 72 publications

References 20 publications

Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy

Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy

A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study

Levetirasetam for the Treatment of Refractor Neonatal Seizures

Contact Info

Product

Resources

About